Eli Lilly has signed a research collaboration and license agreement with Hong Kong-listed METiS TechBio to develop tissue-specific drug delivery technologies, a deal METiS disclosed on October 19 that could generate about $1.1 billion in milestone payments. METiS will receive an upfront payment in the low double-digit millions of US dollars, is eligible for up to about $1.1 billion in development, regulatory and commercial milestone payments, and for tiered royalties at a single-digit percentage of annual net sales of products arising from the work, according to the announcement carried by Reuters and both trades.
The asset Lilly is buying is METiS’s AiLNP platform, an AI-driven system for discovering and optimising ionisable lipids used to build lipid nanoparticles, the tiny carriers that transport molecules such as mRNA or gene-editing agents into cells. The platform combines a large lipid library, end-to-end screening and a lipid language model, and the companies say computational screening can shorten the path from in silico design to in vivo validation. METiS will apply the platform to identify tissue-targeted LNP systems for Lilly-selected programs; Lilly takes responsibility for further development and commercialisation.
The partners did not disclose which of Lilly’s drugs they intend to package into these particles, what diseases they are targeting, how many programs the collaboration covers, or any timetable. No drug candidate covered by the agreement has been identified publicly, and nothing arising from it has entered clinical testing.
For Lilly, the deal fits a year-long pattern of building delivery capability alongside AI, funded by GLP-1 sales. Fierce Biotech noted that 2026 alone has brought Lilly collaborations with QurCan Therapeutics on blood-brain-barrier delivery, Entos Pharmaceuticals on neurological delivery, and academic work on LNP stability, plus the acquisitions of Verve Therapeutics and Engage Biologics, both of which came with genetic-material delivery technology. The hard part remains experimental validation: LNP composition affects delivery efficiency and tolerability, and computational screening narrows the field of formulations to test in the lab, but it does not replace the testing. That is why the upfront cash, not the headline total, is the number that matters for now.